Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2014

Conditions
Prostate Cancer
Interventions
DEVICE

Integrated Imaging High Intensity Focused Ultrasound

DEVICE

Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)

Cryotherapy

Trial Locations (15)

10021

Sloan-Kettering Institute, New York

11215

Brooklyn Urology Research Group, Brooklyn

23235

Virginia Urology Center, Richmond

27599

University of North Carolina, Chapel Hill

27710

Duke University Medical Center, Durham

29572

Carolina Urologic Research Center, Myrtle Beach

34474

Florida Foundation for Healthcare Research Inc, Ocala

53226

Medical College of Wisconsin, Inc., Milwaukee

76017

Urolgoy Associates of North Texas, Arlington

77230

The University of Texas M.D. Anderson Cancer Center, Houston

80010

Univeristy of Colorado Hospital and Health Science Center, Aurora

91006

Chinn & Chinn Urology Associates, Arcadia

37232-2765

Vanderbilt University Medical Center, Nashville

L8N 4A6

Maple Leaf HIFU, Hamilton

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EDAP TMS S.A.

INDUSTRY

NCT00295802 - Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer | Biotech Hunter | Biotech Hunter